Citations

Institution: Mayo Clinic Clear

Showing 10 of 108104 citations.

A Patient With Risk Factors for Barrett’s Esophagus (BE) Undergoes Screening With a Cellular Collection Device
Bartram, Alexander , O’Donovan, Maria , Fitzgerald, Rebecca C. , Katzka, David A.

Foregut: The Journal of the American Foregut Society | July 9, 2025 | Volume: 5 | Issue: 3 | Pages: 300-305

10.1177/26345161251354937 Get It

Minimally invasive esophageal cellular collection devices such as the Capsule Sponge may offer the potential for targeted screening of high-risk patients. The capsule sponge has been shown to be a safe, accurate and effective means of detecting Barrett’s esophagus. Here, we explore two potential real-life scenarios that could occur in a future screening or case finding programme. Firstly, when the capsule sponge test result is positive but confirmatory endoscopy demonstrates <1cm of columnar epithelium and secondly when subsequent endoscopy identifies gastric intestinal neoplasia. We discuss the clinical implication of the result and suggest how these patients could potentially be followed up in the future.
GLP-1 Receptor Agonist Use Is Associated With Small Intestinal Bacterial Overgrowth and Intestinal Methanogen Overgrowth
Fredrick, Thomas , Ospina-Velasquez, Luis, Fredrick, Thomas W , Damianos, John , Jin, Mauricio F. , Wang, Xiao Jing

Foregut: The Journal of the American Foregut Society | July 9, 2025 | Volume: 5 | Issue: 4 | Pages: 433-437

10.1177/26345161251353437 Get It

Introduction: Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP1RAs) are increasingly used to treat obesity and other metabolic conditions; however, they are known to inhibit gastrointestinal motility. Since gastrointestinal microbial overgrowth (MO) can arise in states of intestinal stasis, we sought to investigate the potential association between GLP1RA use and MO. Methods: We analyzed data from 99 patients prescribed GLP1RAs who subsequently underwent testing for MO via intestinal aspirate culture or glucose or lactulose breath tests. Results: Most patients had diabetes. Among patients who underwent culture, 76.2% tested positive for small intestinal bacterial overgrowth (SIBO) at a threshold of ≥10³ CFU/mL, with a significant association found between proton pump inhibitor (PPI) use and SIBO. At ≥10 5 CFU/mL, 33.3% tested positive for SIBO, and neither PPI use nor surgical history was associated. Breath testing revealed a 30.6% positivity rate for MO, predominantly characterized by intestinal methanogen overgrowth (IMO). There was no association between control of diabetes and positive MO tests. Conclusion: GLP1RA use is associated with SIBO, although diabetes may be a confounder.
Devices and techniques for bariatric and metabolic endoscopy: European Society of Gastrointestinal Endoscopy (ESGE) Technical and Technology Review
Boškoski, Ivo , Shamah, Steven, Bove, Vincenzo , Siena, Martina De , Huberty, Vincent , Perretta, Silvana , Pontecorvi, Valerio , Stier, Christine , Sharaiha, Reem Z. , De Siena, Martina , Huberty, Vincent , Sharaiha, Reem Z , Facciorusso, Antonio , Fuccio, Lorenzo , Costamagna, Guido , Matteo, Maria Valeria , Dayyeh, Barham K. Abu , Maselli, Roberta , Facciorusso, Antonio , Fuccio, Lorenzo

Endoscopy | July 9, 2025 | Volume: 57 | Issue: 09 | Pages: 1033-1055

10.1055/a-2630-2062 | PMID 40628371 Get It

Abstract Endoscopic bariatric and metabolic therapies (EBMTs) are increasingly recognized as valuable tools for managing obesity and related metabolic disorders. As the prevalence of obesity continues to rise globally, there is a growing demand for effective, safe, and less invasive treatment options. This review provides a comprehensive summary of the available EBMTs, including both stomach-targeted and small-bowel-targeted devices. The review details the various devices, outlines the techniques for their proper use, and discusses their indications. It also presents data on their efficacy and safety, and the management of adverse events and weight regain, as well as anticipated future developments. The paper emphasizes the necessity for additional high quality randomized controlled trials and long-term outcome data to better define the role of these therapies within obesity treatment protocols. Overall, this review serves as an authoritative resource for endoscopists, bariatric specialists, and the wider healthcare community involved in obesity care, promoting best practices and guiding the appropriate implementation of EBMTs in clinical settings.
Survival Outcomes and Impact of Targeted PAH Therapy in Portopulmonary Hypertension in the PVRI GoDeep Meta‐Registry
Jose, Arun , Yogeswaran, Athiththan , Fünderich, Meike , Kiely, David G. , Sweatt, Andrew J. , Zamanian, Roham T. , Mouawad, Antoine , Balasubramanian, Aparna , Wilkins, Martin R. , Olschewski, Horst , Eichstaedt, Christina A. , Sіrenko, Yu.M. , Majeed, Raphael W. , Wilhelm, Jochen , Tello, Khodr , Elwing, Jean , Seeger, Werner , Thenappan, Thenappan , Ghouleh, Imad Al , Fuenderich, Meike , Kiely, David , Mouawad, Antoine , Wilkins, Martin , Sahay, Sandeep , Giannakoulas, George , Cajigas, Héctor , Frantz, Robert P , Ghio, Stefano , Majeed, Raphael W , Tello, Khodr , Elwing, Jean M , Seeger, Werner , Olschewski, Horst , Thenappan, Thenappan , Jose, Arun , Yogeswaran, Athiththan , Balasubramanian, Aparna , Hassoun, Paul M. , Lawrie, Allan , Howard, Luke , Sahay, Sandeep , Kovács, Gábor , Saleh, Khaled Musa Mohammad , Sabbour, Hani Mohamed , Grünig, Ekkehard , Arvanitaki, Alexandra , Torbas, O.O. , Frantz, Robert P. , Scelsi, Laura , Ghio, Stefano , Ghofrani, Hossein Ardeschir , Grimminger, Friedrich

Pulmonary Circulation | July 9, 2025 | Volume: 15 | Issue: 3 | Pages: No page available

10.1002/pul2.70121 | PMID 40636151 Get It

ABSTRACTPortopulmonary hypertension (PoPH), a type of pulmonary arterial hypertension (PAH) in patients with liver disease, is associated with high morbidity and mortality. The relationship between cardiopulmonary hemodynamics, PAH therapy, and survival in PoPH remains unclear. We performed a retrospective cohort study of PoPH patients from the international pulmonary hypertension (PH) meta‐registry, PVRI GoDeep. PAH was defined by a mean pulmonary arterial pressure > 20 mmHg, pulmonary arterial wedge pressure ≤ 15 mmHg, and a pulmonary vascular resistance (PVR) > 2 Wood Units. PoPH diagnoses were assigned by each center's PH specialist based on international guidelines at the time of enrollment. 246 incident PoPH patients met eligibility criteria and were included in the analysis, equally split between males (51%) and females (49%), with a median age of 54 years. When compared to both patients with IPAH and those with other subtypes of PAH (not classified as PoPH or IPAH), those with PoPH had significantly lower 5‐year survival rates (46% vs. 68% vs. 65%, log‐rank p < 0.001). Amongst the PoPH patients, however, there was no significant difference in 5‐year survival when dichotomized by disease severity, either by a PVR of 5 Wood Units or a CI of 2.5 L/min/m2. Treatment of the PoPH patients with PAH‐targeted therapies was associated with significantly higher 5‐year survival rates compared to those not receiving such treatments, as shown by Kaplan–Meier analysis. This survival benefit was observed for PDE5i (50% vs. 34%, log‐rank p = 0.029), ERA (58% vs. 34%, log‐rank p < 0.001), and the combination of PDE5i and/or ERA (51% vs. 22%, log‐rank p < 0.001), as well as any PAH‐targeting treatment (50% vs. 26%, log‐rank p = 0.007). Corresponding survival advantage was noted when including only PoPH patients with MELD Score ≥ 13. PoPH is a disease with significantly worse long‐term survival than other PAH subtypes, but targeted PAH therapy is associated with a robust survival benefit. Survival did not differ across high‐risk PVR and cardiac index thresholds, suggesting the factors that influence prognosis and survival in PoPH may be unique as compared to other PAH subtypes, and warrant further investigation.
Assessment of a Deep Learning Model Trained on Permanent Pathology for the Classification of Squamous Cell Carcinoma in Mohs Frozen Sections: Lessons Learned
Choudhary, Anirudh , Nassir, Shams , Yousif, Miranda , Hughes, Alysia , Kechter, Jacob , Leibovit-Reiben, Zachary , Stockard, Alyssa , Vidal, Nahid Y. , Rios-Duarte, Jorge A, Kechter, Jacob A, Rios‐Duarte, Jorge A. , Iyer, Ravishankar K. , Leibovit‐Reiben, Zachary , Mangold, Aaron R.

Dermatologic Surgery | July 9, 2025 | Volume: 52 | Issue: 1 | Pages: 31-35

10.1097/dss.0000000000004758 | PMID 40631753 Get It

BACKGROUND There is a scarcity of artificial intelligence models trained on frozen pathology. One way to expand the clinical utility of models trained on permanent pathology is by applying them to frozen sections and fine-tune based on weaknesses. OBJECTIVE To qualitatively evaluate a deep learning model trained on permanent pathology to classify squamous cell carcinoma on Mohs surgery frozen sections to learn model shortcomings and inform retraining and fine-tuning. MATERIALS AND METHODS The authors trained a model for classification of tumor on 746 skin biopsy slides and tested it on 15 Mohs surgery frozen sections. The authors estimated performance metrics and compared the regions of interest generated by the model with the original H&E slides. RESULTS The model achieved an AUC-ROC of 0.985 and 0.796 for tumor classification in permanent pathology and in frozen sections, respectively. Regions of interest for frozen sections with scarce tumor areas were inaccurate, focusing on normal tissue for slides classified as false negative, or highlighting structures different from tumor (e.g., inflammation, muscle, and nerves) for slides classified as true positive. CONCLUSION Deep anatomical structures more commonly present in Mohs frozen pathology might represent data out-of-distribution for models trained on permanent pathology, potentially leading to inadequate model outputs.
Pulsed Field Ablation for Atrial Fibrillation in Fontan Palliation
Deshmukh, Abhishek , Tsai, Shane, Deshmukh, Abhishek J , Khalil, Fouad

Journal of Cardiovascular Electrophysiology | July 9, 2025 | Volume: 36 | Issue: 9 | Pages: 2437-2439

10.1111/jce.16795 | PMID 40631709 Get It

ABSTRACTIntroductionPulsed‐field ablation (PFA) is a novel and effective modality for ablation in patients with atrial fibrillation (AF). Available case reports and small series showed promising results in patients with congenital heart disease. However, PFA ablation in Fontan patients has not been reported yet.Methods and ResultsWe present a 35‐year‐old patient with a history of Fontan palliation for hypoplastic left heart who underwent successful ablation for AF with PFA. We describe procedure characteristics and illustrate the potential benefits of PFA in this patient population.ConclusionWe present a case of PFA for AF in Fontan palliation. PFA was feasible and successful in our case. Long‐term outcomes are yet to be determined.
Both Linear and Area-based Methods Provide an Accurate and Reliable Measurement of Anterior Shoulder Instability Related Glenoid Bone Loss
Barret, Hugo , Niggli, Luzia Anna , Athwal, George S. , Hartzler, Robert U. , Sánchez‐Sotelo, Joaquín , Lambers, Floor M. , Sanchez-Sotelo, J.

JBJS Open Access | July 8, 2025 | Volume: 10 | Issue: 3 | Pages: No page available

10.2106/jbjs.oa.25.00022 | PMID 40630743 Get It

Background: Recurrent anterior shoulder instability may lead to capsuloligamentous and bony lesions of the glenoid and humerus. To date, there is no clear consensus on how to best measure anterior glenoid bone loss (GBL) in the setting of recurrent instability. The objective of this study, therefore, was to evaluate the accuracy and reliability of 7 different methods of measuring anterior GBL on three-dimensional models based on computed tomography. Methods: Eight levels of GBL in the anterior and anteroinferior directions were virtually generated in 14 three-dimensional healthy glenoid models. GBL was measured with 7 different methods: based on a height/width ratio (M1), based on surface area within a circle (M2 and M3), based on linear distance within a circle, (M4, M5, and M6), and based on a volume ratio (M7). For each method, the measurement accuracy was assessed by comparing the calculated value with the true amount of generated GBL. The measurement reliability was assessed by computing the score variance and intraclass correlation coefficient. Results: The most accurate (average measurement error of <2% and largest proportion with error <5%) and reliable (ICC >0.96) measurement methods for GBL were M2 (based on surface area) and M5 (based on the linear distance). The average measurement error for the other methods ranged between 3% and 11% for anterior GBL and between 2% and 9% for anteroinferior GBL. For anterior GBL, the measurement increased by an average of 0.5% for each 1% increase in circle radius, leading to an overestimation of GBL with a larger circle diameter Conclusion: The methods for calculating glenoid bone loss performed better for the more common direct anterior bone loss rather than the less common anteroinferior-directed bone loss. Both an area-based method (M2) and linear distance–based method (M5) resulted in accurate and reliable measurements of glenoid bone loss; however, the linear distance–based methods may be easier to perform clinically. The height-width ratio and volume methods were less accurate and reliable. Level of Evidence: Level IV ; case series; diagnostic studies. See Instructions for Authors for a complete description of levels of evidence.
Dissecting the biology of gliomagenesis: Evaluating the interaction between IDH tumor mutation and germline variants
Kosel, Matthew , Decker, Paul A. , Kollmeyer, Thomas M. , Shurtz, Anne K., Molinaro, Annette M. , Moassefi, Mana , Wrensch, Margaret , Jenkins, Robert B. , Eckel‐Passow, Jeanette E. , Vaubel, Rachel A, Jenkins, RB , Eckel-Passow, Jeanette E , Kollmeyer, Thomas , Decker, Paul A. , Drucker, Kristen , Molinaro, Annette M. , Conte, Gian Marco , Moassefi, Mana , Erickson, Bradley J. , Wiencke, John K. , Francis, Stephen , Burns, Terry C. , Vaubel, Rachael A. , Lachance, Daniel Honore , Tobin, W. Oliver

Neuro-Oncology Advances | July 8, 2025 | Volume: 7 | Issue: 1 | Pages: No page available

10.1093/noajnl/vdaf147 | PMID 40709013 Get It

Abstract Background The CCDC26 germline variant rs55705857 is causal for development of IDH mutant (IDHmut) adult glioma. However, ~60% of IDHmut patients do not carry the rs55705857 risk allele. We aimed to identify variants associated with developing IDHmut glioma among patients that do not have the rs55705857 risk allele and to further understand development of IDHwt glioma. Methods We used three datasets that included 1216 IDHmut and 1442 IDHwt glioma patients and a case–case design to perform genome-wide association (GWAS) analyses comparing IDHmut versus IDHwt glioma. Analyses were performed overall and stratified by rs55705857 genotype and sex. Multivariable logistic regression and regression trees were used to develop models to predict IDH status using germline variants, age, and contrast enhancement on MRI. Results Three regions were identified comparing IDHmut versus IDHwt: rs55705857 (meta P-value [P] = 1.35 × 10−43), PHLDB1 (rs7125115, P = 3.46 × 10−17), and D2HGDH (rs71430382, P = 2.43 × 10−12). When analyzing only patients that do not have the rs55705857 risk allele, PHLDB1 (rs7125115, P = 1.73 × 10−13) and D2HGDH (rs71430382, P = 8.86 × 10−10) were identified. Among patients who have the rs55705857 risk allele, four variants between ROBO1 and ROBO2 (rs4680975, P = 4.65 × 10−7) increased the likelihood of having an IDHwt tumor. Tumor expression of ROBO1 was associated with rs4680975 genotype in IDHwt patients that have the rs55705857 risk allele (P = 0.034). Multivariable logistic analysis demonstrated that rs55705857, rs71430382 (D2HGDH), and age predicted IDH mutation status. Conclusions To understand the development of adult glioma, we demonstrate that D2HGDH and PHLDB1 should be prioritized for functional studies in IDHmut tumors. The ROBO1 region warrants further investigation in IDHwt tumors.
A Signal for Voice and Speech Abnormalities in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
Grach, Stephanie L. , Seltzer, J. L. , Orbelo, Diana M. , Seltzer, Jaime , Grach, Stephanie L , Orbelo, Diana

Journal of Clinical Medicine | July 8, 2025 | Volume: 14 | Issue: 14 | Pages: 4847

10.3390/jcm14144847 | PMID 40725538 Get It

Background/Objectives: Patients with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) may report abnormalities in voice and speech; however, no formal research has been conducted in this area. Methods: An online mixed-methods survey was completed by 685 people with ME/CFS. A total of 302 respondents completed the qualitative component (44.09%). Questions assessed disease experience with ME/CFS and post-exertional malaise without prompting on specific symptoms. Within the qualitative results, a search of the terms “speech, voice,” “words,” and “speak” was conducted. Results: Excluding neurocognitive associations, colloquial phrases, and “speech therapy,” there were 38 mentions of the terms in the context of voice or speech changes across 28 unique qualitative survey responses (9.27%). Conclusions: A notable portion of respondents reported voice or speech changes when responding to open-ended qualitative questions about their disease experience. More research is needed regarding the implications of voice and speech anomalies in ME/CFS pathology and disease monitoring.
The Angiography Pattern of Buerger’s Disease: Challenges and Recommendations
Fazeli, Bahare , Poredoš, Pavel , Stephen, Edwin , Bashar, Abul Hasan Muhammad , Kozak, Matija, Catalano, M. , Salman, Mussaad Mohammaed Al, Altarazi, Louay, Dimakakos, Evangelos , Erer, Dilek , Farkas, Katalin , Fokou, Marcus , Ionac, Mihai , Iwai, Takehisa , Karahan, Oğuz , Kashani, Daniel , Kota, Albert Abhinay , Kröger, Knut , Kubat, Emre , Premkumar, Prabhu , Marcoccia, Antonella , Pandey, Sandeep Raj , Patel, Malay , Pécsvárady, Zsolt, Polat, Adıl , Ravari, Hassan , Selvaraj, Dheepak, Sharebiani, Hiva , Stanek, Agata , Taha, Wassila , Taheri, Hossein , Yuwono, Hendro Sudjono , Zor, Mustafa Hakan , Stephen, Edwin , Bashar, Abul Hasan Muhammad , Catalano, Mariella , Dimakakos, Evangelos , Farkas, Katalin , Ionac, Mihai , Karahan, Oguz , Kashani, Daniel , Kota, Albert , Kubat, Emre , Kumar, Prabhu Prem , Marcoccia, Antonella , Polat, Adil , Ravari, Hassan , Sharebiani, Hiva , Stanek, Agata , Liew, Aaron , Antignani, Pier Luigi , Desai, Sanjay, Hüssein, Emad , Małecki, Rafał , Schernthaner, G. , Szuba, Andrzej

Journal of Clinical Medicine | July 8, 2025 | Volume: 14 | Issue: 14 | Pages: 4841

10.3390/jcm14144841 | PMID 40725544 Get It

In 2023, the VAS international working group on Buerger’s Disease (BD) recommended two diagnostic criteria based on a prior Delphi study: “definitive” and “suspected”. The “definitive” criteria are history of smoking, typical angiography, and typical histopathological features. All three features are mandatory to confirm a “definitive” diagnosis of BD. The conundrum is—what features should be considered typical of BD angiography? According to this review, segmental occlusion of infrapopliteal arteries, corkscrew collaterals that appear to continue the occluded arterial segment (Martorell’s sign) or bypass the segmental occlusion, absence of atherosclerotic plaque or aneurysm could differentiate BD from ASO. Hence, for “typical” BD angiography, these manifestations should certainly be considered. However, data for differentiating angiography patterns of BD from the small- and medium-sized vasculitis including Behcet’s disease, scleroderma, hepatitis associated vasculitis, and anti-phospholipid syndrome are limited. Further studies for investigating the angiography pattern in BD patients in early and late presentation of BD, particularly in the patients with long-term follow up, are highly recommended.